Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,307 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05532813RecruitingPhase 3
Metformin for adult myotonic dystrophy type 1 muscle weakness
This Phase 3 trial tests whether metformin can improve symptoms and safety in adults with genetically confirmed myotonic dystrophy type 1 (DM1). It may help reduce muscle problems, but you must meet specific walking, breathing, heart, and kidney requirements.
GarchesAges 18–70 - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05904119RecruitingPhase 3
Lomustine with or without re-irradiation for recurring glioblastoma
This trial studies whether adding repeat radiation (called re-irradiation) to the chemotherapy medicine lomustine can slow or control glioblastoma that has returned or progressed after standard treatment. It’s designed for people whose tumor comes back at least 6 months after their last radiation.
InnsbruckAges 18 years+ - NCT05884476Recruiting
Re-checking suicidal thoughts in Veterans during a study
This study looks at a way to re-evaluate and respond to suicidal thoughts in Veterans. It may help improve how support is offered when someone has had thoughts of suicide recently.
New Orleans, LouisianaAges 18 years+ - NCT05902221RecruitingPhase 3
Rifampicin add-on for knee, hip, or shoulder implant infections
This Phase 3 trial tests whether adding rifampicin improves outcomes for implant infections caused by a specific germ (Cutibacterium acnes) after surgery. If you have such an infection and the germ is susceptible, you may be able to receive a rifampicin-based treatment plan.
AnnecyAges 18 years+ - NCT05880212Recruiting
STOPS low back and leg pain approach for Bangladesh
This trial tests a specific physiotherapy program (“STOPS approach”) for people with long-lasting low back pain or leg pain from the back. It aims to see if the structured treatment, delivered by trained physiotherapists, improves pain and function over about 10 weeks.
Dhaka, UttaraAges 18–65 - NCT05900271Recruiting
Trial for depression using new brain-stimulation sessions
This study tests whether a specific type of brain stimulation (theta burst delivered over several days) works better than standard rTMS given over 6 weeks for people with treatment-resistant depression. It may help improve depressive symptoms, measured with multiple depression rating scales.
Nijmegen, GLAges 18–99 - NCT05898308RecruitingPhase 4
Test a personalized maintenance plan for pemphigus
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
AmiensAges 18–80 - NCT05885932Recruiting
Stent treatment versus medicines for blocked neck artery
This study compares a drug-coated stent placed in a neck (vertebral) artery versus best medical treatment with medicines and risk-factor control. It aims to reduce problems caused by a badly narrowed artery after recent stroke-like symptoms.
BeijingAges 18 years+ - NCT05904782Recruiting
Brief positive-activity coaching for caregivers of advanced cancer
This trial tests a short program meant to support caregivers’ positive feelings while they care for someone with stage IV cancer. If you’re eligible, you may be asked to complete study activities by phone or internet for a set period of time.
Houston, TexasAges 18 years+ - NCT05891821RecruitingPhase 2
Balstilimab for relapsed lymphoma after standard treatments failed
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
YerevanAges 18 years+ - NCT05878314Recruiting
Testing how hormones and tumor markers guide breast cancer treatment
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
TübingenAges 18 years+ - NCT05880914Recruiting
Personalized treatment study for bone disease in kidney failure
This trial looks at a personalized approach to diagnosing and treating bone problems caused by long-term kidney disease. It may help by matching treatment plans to the type of bone turnover found in your tests or biopsy.
St Louis, MissouriAges 18 years+ - NCT05905146Recruiting
Personalized opioid plan to shorten treatment time
This trial tests whether a personalized medication plan can help patients with short-term, non-cancer muscle or joint pain need strong opioid medicine for a shorter time. It’s aimed at improving how long treatment lasts while still managing pain.
LilleAges 18 years+ - NCT05890677Recruiting
Surgery versus conservative care for chronic breast-related arm swelling
This trial compares microsurgery to standard conservative therapy for long-lasting arm swelling caused by prior breast cancer. It may help people who still have swelling despite months of decongestive treatment by improving quality of life.
New Haven, ConnecticutAges 18 years+ - NCT05901818RecruitingPhase 1
Testing a patient’s own stem-cell treatment for Parkinson’s
This Phase 1 study tests whether an “autologous” (from your own body) iNSC-DAP stem-cell treatment is safe and may help symptoms in Parkinson’s disease. It is designed mainly to check safety, while also watching for signs of improvement.
Beijing, Beijing MunicipalityAges 30–85 - NCT05905705Recruiting
ECT plus a sleep monitor for treatment-resistant depression
This study looks at how electroconvulsive therapy (ECT) affects brain activity and sleep patterns in people with difficult-to-treat depression. It uses a wearable sleep monitor (the Dreem device) to record sleep while you receive ECT.
St Louis, MissouriAges 21–65 - NCT05909709RecruitingPhase 1
Tested injections for chronic facet-related back pain
This Phase 1 study tests the safety of an injection called Alocyte in adults with long-lasting back pain coming from the facet joints. If you qualify, you may be followed closely to check side effects and how you respond over multiple visits.
North Miami, FloridaAges 18 years+ - NCT05895136RecruitingPhase 2
Albumin plus blood thinner for severe cirrhosis after hospital recovery
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
ClichyAges 18–80 - NCT05901974RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed ALAL
This Phase 2 study tests whether venetoclax combined with azacitidine can help people with ALAL (an “ambiguous” type of acute leukemia). It also checks whether the combination is safe for newly diagnosed patients with adequate heart, liver, and kidney health.
SuzhouAges 15 years+ - NCT05910580Recruiting
Screening and support for alcohol and substance risk in adults
This study aims to improve care access and outcomes for adults who screen positive for risky alcohol or drug use. If you qualify, you may be offered ways to connect to support during your reproductive years.
Boston, MassachusettsAges 18 years+
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,307 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.